{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477860094
| IUPAC_name = (''RS'')-2-[4-(2-thienylcarbonyl)phenyl]propanoic acid
| image = suprofen.svg
| width =
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|suprofen}}
| pregnancy_US = C
| legal_status = Discontinued
| routes_of_administration = Oral, eye drops
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 20%
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers-->
| IUPHAR_ligand = 7298
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 40828-46-4
| ATC_prefix = M01
| ATC_suffix = AE07
| ATC_supplemental =  
| PubChem = 5359
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00870
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 5166
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 988GU2F9PE
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00452
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 9362
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 956
<!--Chemical data-->
| C=14 | H=12 | O=3 | S=1
| molecular_weight = 260.309 g/mol
| SMILES = O=C(c1ccc(cc1)C(C(=O)O)C)c2sccc2
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = MDKGKXOCJGEUJW-UHFFFAOYSA-N
}}

'''Suprofen''' is a [[nonsteroidal anti-inflammatory drug]] (NSAID) developed by [[Janssen Pharmaceutica]]<ref>[[Paul Janssen|Janssen, Paul A.]]; Van Daele, Georges H. P.; Boey, Jozef M.  "Antiphlogistic aroyl-substituted phenylacetic acid derivatives"  (1974)  {{cite patent|DE|2353357}}</ref> that was marketed as 1% eye drops under the [[trade name]] '''Profenal'''.

==Uses==
Suprofen was originally used as [[Tablet (pharmacy)|tablet]], but oral uses have been discontinued due to [[renal]] effects.<ref>{{cite journal | title = Renal effects of nonsteroidal anti-inflammatory drugs | author = Nies A S | journal = Agents and actions | year = 1988 | volume = 24 | pages = 95â€“106 | doi=10.1007/978-3-0348-9160-8_9 | pmid=3142236}}</ref>  It was subsequently used exclusively as a [[topical]] [[Ophthalmology|ophthalmic]] solution, typically to prevent [[miosis]] during and after ophthalmic [[surgery]].<ref>[http://www.fda.gov/ora/compliance_ref/cpg/cpgdrg/cpg460-200.html Guidance for FDA Staff and Industry Compliance Policy Guides Manual], Sec. 460.200</ref> This application has been discontinued as well, at least in the US.<ref>Drugs.com: [http://www.drugs.com/mtm/suprofen-ophthalmic.html suprofen ophthalmic]</ref>

==References==
<references/>

{{Anti-inflammatory and antirheumatic products}}
{{Prostanoidergics}}

[[Category:Nonsteroidal anti-inflammatory drugs]]
[[Category:Thiophenes]]
[[Category:Propionic acids]]
[[Category:Aromatic ketones]]
[[Category:Janssen Pharmaceutica]]


{{musculoskeletal-drug-stub}}